HONOLULU & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Results of a ground-breaking study quantifying the economic, individual and societal burden of hereditary angioedema (HAE) bring to light the substantial direct and indirect costs of the disease on patients and society. The study reveals a compelling need for new and better therapies to ameliorate the devastating impact of this potentially life-threatening condition which is characterized by acute attacks of swelling that is often accompanied by excruciating pain. Findings from this study, which evaluated feedback collected from 457 HAE patients, were presented yesterday at the 2008 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), in Seattle, WA. The study was conducted jointly by the United States Hereditary Angioedema Association (HAEA) and Dyax Corp. (NASDAQ:DYAX).
